Technique May Allow Half-matched Donors in Stem Cell Transplants

A new technique appears to make possible half-matched donors for patients with pediatric acute leukemia – possibly marking a significant step forward in the treatment of these patients.

According to a presentation by Alice Bertaina, M.D., of Bambino Gesu Children's Hospital in Rome, patients needing a stem cell transplantation for acute leukemia may no longer have to wait to find a matched donor. Their parents, each a half-matched donor, may be able to be effective donors.

And this is possible without reducing survival rates.

A new technique

Previously, half-matched donors have met with little success and high rates of infection as well as recurrence of disease. However, Bertaina and colleagues used a technique to physically remove what she called the “bad” cells from the graft by using magnetic beads to draw out a subset of cells involved in causing graft-versus-host disease (GVHD), the so-called alpha/beta-positive T cells and CD19-positive B cells.

What is left behind are largely gamma/delta-positive T cells and natural killer cells. These cells, they found, engraft easily and with low rates of relapse and mortality.

High survival rates

Their study involved 50 children whose parents each donated stem cells. After 35 months, the total incidence of relapse was 19 percent (two patients died), allowing for a leukemia-free survival rate of 77 percent – very comparable to the figures from fully matched transplants.

No cases of stomach or liver acute GVHD developed. However, 13 patients did develop skin-only GVHD of grades I and II, she said.

On top of that, it didn’t matter which parent donated the stem cells.

Source: ASH 2013

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap